Hypoxia-inducible factors (HIFs) are oxygen-dependent transcriptional activators that play crucial roles in angiogenesis, erythropoiesis, energy metabolism, and cell fate decisions. The group of enzymes that can catalyse the hydroxylation reaction of HIF-1 is prolyl hydroxylase domain proteins (PHDs). PHD inhibitors (PHIs) activate the HIF pathway by preventing degradation of HIF-1α by inhibiting PHDs. Osteogenesis and angiogenesis are tightly coupled during bone repair and regeneration. Numerous studies suggest that HIFs and their target gene, vascular endothelial growth factor (VEGF), are critical regulators of angiogenic-osteogenic coupling. In this brief perspective, we review current studies about the HIF pathway and its role in bone repair and regeneration, as well as the cellular and molecular mechanisms involved. Additionally, we briefly discuss the therapeutic manipulation of HIFs and VEGF in bone repair and bone tumours. This review will expand our knowledge of biology of HIFs, PHDs, PHD inhibitors, and bone regeneration, and it may also aid the design of novel therapies for accelerating bone repair and regeneration or inhibiting bone tumours.

1. Introduction

Hypoxia-inducible factors (HIFs) are DNA-binding transcription factors that transactivate a series of hypoxia-associated genes under hypoxic conditions to adapt to the decreased oxygen tension. Under normoxia, HIF-α is hydroxylated by prolyl hydroxylase domain proteins (PHDs), recognised by the ubiquitin E3 ligase, and directed to the proteasome for degradation. Under hypoxia, the catalytic activity of PHDs is inhibited. HIF-α accumulates in the nucleus and dimerises with HIF-β, and together they promote the transcription of hypoxia-response genes [1]. Considering the role of the HIF pathway in angiogenesis, erythropoiesis, cell fate decisions, and cytoprotection, a large number of PHD inhibitors, especially the novel inhibitors of PHD, such as TM6008, TM6089, and FK506-binding protein 38 (FKBP38), have been found and used to activate the HIF pathway and acquire beneficial aspects of the HIF system [2, 3]. Increasing evidence suggests that the HIF pathway plays an essential role in bone regeneration and repair. The initial factor of bone regeneration is the upregulation of HIF-1α induced by hypoxia [4]. Resident cells, including chondrocytes and osteoblasts, sense the reduced oxygen tension via the PHDs and activate the HIFs, thereby increasing oxygen-regulated gene expression, including that of vascular endothelial growth factor (VEGF), to promote angiogenesis and osteogenesis. This review aims at discussing the advances of the HIF pathway, the relationship between angiogenesis and osteogenesis, and the role of the HIF pathway in angiogenic-osteogenic coupling. Moreover, therapeutic manipulation of the HIF pathway for bone fracture, osteoporosis, distraction osteogenesis, and bone tumour will be discussed.

2. Hypoxia-Inducible Factors

Hypoxia-inducible factors are DNA-binding transcription factors that interact with specific nuclear cofactors under hypoxia, and they transactivate a series of hypoxia-associated genes to trigger adaptive responses. HIFs are heterodimers composed of an α subunit and a β subunit [5]. HIF-β is a constitutive subunit expressed in the nucleus, and its activity
is not affected by hypoxia, whereas HIF-α is a functional subunit, and its protein stability, subcellular localisation, and transcriptional potency are affected by oxygen levels [6]. HIFs have three members: HIF-1, HIF-2, and HIF-3, and they have the same β subunit but have different α subunits (HIF-1α, HIF-2α, and HIF-3α, resp.). The structure and functions of HIF-1α are more extensively studied than those of HIF-2α or HIF-3α. HIFs play a central role in the regulation of gene expression by oxygen. Approximately 100 target genes of HIFs have been identified, consisting of erythropoietin (EPO), vascular endothelial growth factor, hemeoxygenase-1 (HO-1), inducible nitric oxide synthase (iNOS), glucose transporter protein 1 (Glut-1), insulin-like growth factor 2 (IGF-2), endothelin 1, transferrin, and others. HIF target genes are particularly relevant to angiogenic factors, proliferation or survival factors, glucose transporters, and glycolytic enzymes [7].

Under normoxia and in the presence of Fe2+ and 2-oxoglutarate, certain conserved proline residues (Pro-402 and Pro-564 in HIF-1α [8, 9]; Pro-405 and Pro-531 in HIF-2α; Pro949 in HIF-3α) within the oxygen-dependent degradation domain (ODD) are hydroxylated by prolyl hydroxylase domain proteins [10–12]. Then, the hydroxylated HIF-α interacts with the β-domain of von Hippel-Lindau tumour suppressor protein (pVHL) and is subsequently ubiquitylated by the pVHL-E3 ligase complex, thereby marking HIF-α for degradation by the 26S proteasome [13, 14]. Under hypoxia, oxygen-dependent proteolytic destruction of the hypoxia-inducible factor-α subunit is abrogated [15]. HIF-α accumulates in the nucleus and dimerises with HIF-β. Together, they interact with the transcriptional coactivators p300/Crebbinding protein and form a transcriptional complex [16, 17]. This transcriptional complex binds to hypoxia-response elements (HREs) comprising a core 5′-(A/G)CGTG-3′ consensus sequence and highly variable flanking sequences in the promoters of hypoxia-response genes [18] and promotes the transcription of hypoxia-response genes, thereby regulating the cellular adaptive response to hypoxia [1].

3. Prolyl Hydroxylase Domain Proteins

The group of enzymes that can catalyse the hydroxylation reaction of HIF-1/α is prolyl hydroxylase domain proteins (PHDs). PHDs play a critical role in regulation of HIFs. PHDs are considered in vivo oxygen sensors insofar as they can sense the concentration of cytosolic oxygen, and they need oxygen in the form of dioxygen for catalytic activity. Under normoxia, PHDs hydroxylate two highly conserved proline residues located within the ODD recognised by the ubiquitin E3 ligase and are directed to the proteasome for degradation. Under hypoxia, PHD activity decreases due to their need for molecular oxygen as a cosubstrate. The PHD subfamily has three members: PHD1, PHD2, and PHD3. A recently characterised prolyl 4-hydroxylase possessing a transmembrane domain named PHD4 or P4H-TM was found to be the fourth member of the PHD subfamily [19]. The investigations of PHD1–3 were more extensive compared to those of PHD4. PHDs belong to a superfamily of iron- and 2-oxoglutarate-dependent dioxygenases, meaning that molecular oxygen, 2-oxoglutarate (2-OG), and iron(II) are required for their catalytic activity. They share a well-conserved hydroxylase domain in their C-terminal halves, whereas the N-terminal halves are more variable and have poorly characterised functions among these three isoforms [20]. They all have the ability to hydroxylate the special proline residues of HIF-α but differ in their substrate specificity and their distribution in tissues and cells. It was reported that PHD2 is more active on HIF-1α than on HIF-2α, whereas PHD1 and PHD3 hydroxylate HIF-2α more efficiently [21].

Interestingly, while PHDs regulate HIF-α protein stability, PHD2 and PHD3 (but not PHD1) are themselves subject to feedback upregulation by HIFs. Studies found that the PHD2 gene contains a hypoxia-response element (HRE) that can be recognised by HIF-1/α, and the PHD3 gene contains a HRE recognised by HIF-2/α [22, 23]. Under hypoxia, PHD2 and PHD3 are upregulated due to HIF-α accumulation [24–26].

4. Prolyl Hydroxylase Domain Protein Inhibitors

In view of the beneficial aspects of the HIF system, PHDs have been considered as therapeutic targets for anaemia and ischemia. PHD inhibitors have been designed and used to activate the HIF pathway and acquire beneficial aspects of the HIF system.

4.1. Nonselective PHD Inhibitors. Because PHDs require iron and 2-oxoglutarate to catalyse HIF prolyl hydroxylation, any compound that competes for endogenous iron(II) or 2-oxoglutarate can be considered a PHD inhibitor. Deferoxamine (DFO) and cobalt chloride (CoCl2), an iron chelator and a competitive inhibitor of iron, respectively, are routinely used both in vitro and in vivo to inhibit PHD activity by competing for endogenous iron(II). Other iron chelators, such as ciclopirox olamine, and competitive inhibitors of iron, such as Cu2+, Zn2+, and Mn2+, are also used as PHD inhibitors [27]. However, they have effects on endogenous iron(II) and impair the activity of both PHD enzymes and other iron-dependent enzymes. Oxogluturate analogues such as L-mimosine (L-mim), dimethylxalylglycine (DMOG), and 3,4-dihydroxybenzoate (3,4-DHB) inhibit PHDs by competing for endogenous 2-oxoglutarate. Many studies based on cells or animals have revealed that oxoglutarate analogues can produce beneficial biological results by stabilising HIFs [28–31]. In recent years, attention has been directed towards identifying small molecule inhibitors of PHDs. Many novel small molecule inhibitors of PHDs, such as FG-2216, FG-4592, FG-4497, and GSK360A, have been recently designed by companies such as GlaxoSmithKline and FibroGen and have achieved good clinical value, especially in the treatment of anemia and ischemia [32–35].

4.2. Novel PHD Inhibitors. In addition to the strongly conserved catalytic site in PHDs, other domains, such as the amino or carboxyl terminal ends, which are highly variable,
Table 1: Approaches to HIF signal enhancement.

| Approach/agent                                      | Remarks                                      | Applications/reference |
|----------------------------------------------------|----------------------------------------------|------------------------|
| Chemical inhibition of PHDs by hypoxia-mimetics    | Operate conveniently                        |                        |
| Iron chelators or iron competitive inhibitors      | Nonspecific; unwanted effects on endogenous iron | [38–44]                |
| DFO                                                |                                              | [45]                   |
| CoCl₂                                              |                                              |                        |
| Oxoglutarate analogues                             | Nonspecific                                 |                        |
| DMOG                                               |                                              | [40]                   |
| L-Mimosine                                         |                                              | [43]                   |
| EDHB                                               |                                              | [46]                   |
| FG-2216                                            |                                              | [47]                   |
| GSK360A                                            |                                              | [35]                   |
| Genetic techniques                                 | Complex procedures; biotic security         |                        |
| Von-Hippel-Lindau knockout                         | Nonspecific                                 | [48, 49]               |
| PHD siRNA transfection                             | PHD-specific                                |                        |
| PHD2 siRNA                                         |                                              | [50, 51]               |
| Constitutively active HIF-α transgenes             | Organ-specific                              | [52, 53]               |

DFO: deferoxamine; CoCl₂: cobalt chloride; DMOG: dimethyloxalylglycine; EDHB: ethyl-3-4-dihydroxybenzoate; FG: fibrogen; GSK: GlaxoSmithKline.

or the protein-protein interaction domain can also be targets for therapeutic intervention. TM6008 and TM6089, two novel PHD inhibitors, were synthesised based on the three-dimensional protein structure of human PHD2. Both of these compounds selectively inhibit PHD2 by binding to the active site within PHD2 where HIFs bind and stimulate HIF activity [2]. The FK506-binding protein 38 (FKBP38) has been demonstrated to decrease PHD2 protein stability through interaction with N-terminal domain of PHD2 [3]. MAPK organiser 1 (Morg1), as a molecular scaffold of PHD3, also specifically interacts with the N-terminal region of PHD3 [36].

4.3. Untoward Effects of PHD Inhibitors. Currently available PHD inhibitors are all nonselective and nonspecific. They will certainly inhibit other 2-OG- or iron(II)-dependent oxygenases and other PHD isoforms, resulting in unwanted side effects. Moreover, recent findings have shown that, in addition to HIFs, PHDs interact with various other proteins including FKBP38 and Morg-1. Thus, treatment with PHD inhibitors has the potential to disrupt not only PHDs but also potential non-HIF substrates. VEGF, one important HIF target gene, is believed to play an important role in tumour angiogenesis and subsequent tumour growth [37]. High levels of EPO, another important HIF target gene, are closely linked to cardiovascular events and thromboembolic events. Therefore, it will be important to weigh the advantages and disadvantages when considering using PHD inhibitors as a therapy.

In addition to PHD inhibitors, many methods used to enhance the HIF pathway activity have been experimentally applied. The most common approaches used to activate HIFs are listed in Table 1, and their advantages and disadvantages are summarised.

5. Role of the HIF Pathway in Angiogenic-Osteogenic Coupling

Bone is a highly vascularised tissue and receives 5–20% of resting cardiac output [54, 55]. The progress of bone repair and regeneration is closely associated with that of vessel ingrowth. The blood vessels supply oxygen and nutrients to the regenerating bone and mediate interactions between osteoblasts, osteocytes, osteoclasts, mesenchymal stem cells, and vascular endothelial cells.

Recently, numerous investigations have been undertaken, and it was demonstrated that HIF-1α and its target gene VEGF are critical regulators of angiogenic-osteogenic coupling [56].

Hypoxia is a major driving force for angiogenesis by stabilising HIFs during endochondral bone formation [57]. Schipani et al. investigated the functions of HIF-1α in the cartilaginous growth plate of developing bone [58]. They found that the developmental growth plate is hypoxic and expresses HIF-1α and that tissue-specific deletion of HIF-1α via the expression of the Col2-Cre transgene induced a massive increase in epiphyseal chondrocyte death, indicating that HIF-1α is required for survival in this hypoxic tissue. In addition to chondrocytes, osteoblasts also express HIF-1α and promote skeletal vascularisation during endochondral bone formation. Wang et al. observed the effects of gain or loss of HIF function by genetically disrupting the expression of the E3 ligase VHL or HIF-1 in osteoblasts to study the role of the HIF pathway in angiogenic-osteogenic coupling during skeletal development [59]. They found that mice that lack VHL in osteoblasts and that therefore overexpress HIFs show striking and progressive increases in bone volume. In contrast, mice lacking HIF-1 in osteoblasts show decreased bone diameter and significant reductions in osteoid volume.
Interestingly, the amount of bone in these mutant mice is directly proportional to the amount of vascularisation and VEGF mRNA levels, suggesting that the regulation of bone mass may be secondary to changes in VEGF levels and angiogenesis and that HIFs and VEGF play a critical role in angiogenic-osteogenic coupling during skeletal development.

HIFs promote angiogenesis and osteogenesis by trans-activating VEGF and other HIF target genes [59]. Recent studies have demonstrated that chondrocytes, osteoblasts, and mesenchymal stem cells (MSCs) sense reduced oxygen tension via the HIF pathway and transmit signals involved in angiogenic and osteogenic gene programs during bone repair and regeneration [49]. Interestingly, the HIF pathway also has effects on osteoblasts and mesenchymal stem cells (MSCs) independent of angiogenesis. HIFs promote the proliferation, migration, and survival of MSCs, but they inhibit the osteogenic and adipogenic differentiation of MSCs [60]. Recently, HIF-1α has been shown to regulate MSC proliferation through the enhancement of TWIST expression, which downregulates the E2A-p21 pathway and thereby increases proliferation of MSCs [61]. The HIF pathway increases the expression of the chemokine receptors CXCR4 and VEGFR1, thereby promoting the SDF-1α- and VEGF-dependent migration of MSCs [62, 63]. HIFs inhibit the osteogenic and adipogenic differentiation of MSCs by decreasing the expression of RUNX2 and PPAR-γ2 [64–66]. It is suggested that the glucose 6-phosphate transporter (G6PT), which is activated by HIFs, enables MSCs to survive under hypoxic conditions by increasing their metabolic flexibility [67]. The effects of HIFs on MSCs are summarised in Figure 1. It has been revealed that VEGF, a target gene of HIFs, also has effects on MSC properties. VEGF promotes the proliferation, migration, and survival of MSCs, and it induces osteogenic but decreases adipogenic differentiation of MSCs [68–73]. Moreover, VEGF promotes osteoblast proliferation, survival, and migration and acts as a potent chemoattractant to induce migration in cultured osteoblasts [74, 75].

The relationship between osteoprogenitor and endothelial cells has been recently studied. Mesenchymal stem cells can provide a local environment that favours migration and formation of tubular structures of endothelial cells [76]. Moreover, mesenchymal stem cells promote the migration, extracellular matrix invasion, proliferation, and survival of endothelial cells [77]. Interestingly, endothelial cells also have effects on bone marrow stromal cells by inducing osteoblast differentiation [78].

6. Applications of HIF Pathway in Bone Repair and Regeneration

As the HIF pathway plays a vital role in angiogenic-osteogenic coupling, manipulation of the HIF system via pharmacological or genetic approaches is an attractive strategy for treating hypoxic-ischemic diseases, including skeletal diseases such as bone fracture.

6.1. Bone Fracture. Fracture, accompanied with disruption of the blood vessels, leads to activation of coagulation and
formation of a haematoma that remarkably promotes angiogenesis. Simultaneously, inflammatory cells are recruited, and inflammatory signals are released to stimulate the recruitment of mesenchymal progenitors that subsequently differentiate into chondrocytes and produce a cartilaginous matrix. VEGF produced in the newly formed cartilaginous callus stimulates neoangiogenesis of the cartilage; then, the hypertrophic chondrocytes undergo apoptosis, which is followed by callus remodelling by newly recruited osteoclasts and replacement with woven bone [79, 80]. Inhibition of angiogenesis during bone repair impedes the replacement of chondrocytes with osteoblasts, resulting in the formation of fibrous rather than mineralised tissue [81].

The upregulation of HIF-1α induced by the interruption of oxygen and nutrient supply has been considered a primary stimulus for new bone formation [4]. Komatsu and Hadjiargyrou demonstrated for the first time that HIF-1α is upregulated at both transcriptional and translational levels in the femoral fracture callus during fracture repair, with peak increases on postfracture day 10 [82]. They indicated that postfracture day 10 might be a key angiogenic time point in the developing rat fracture callus. This result may offer guidance for the clinical treatment of bone fractures. VEGF is also upregulated at fracture sites [83, 84].

Numerous studies have shown that fracture repair can be promoted via manipulation of HIF pathway activity. Rios et al. found that using siRNA against PHD2 to activate the HIF-1 pathway supports bone regeneration in vivo [50]. They implanted chambers containing silk fibroin-chitosan scaffolds with siRNA against PHD2 over the periosteum. After 70 days, they found that the mean bone volume increased in vivo, suggesting that HIF-1 supports bone regeneration.

VEGF is a key regulator of angiogenesis. VEGF has been safely and efficiently applied to stimulate neovascularisation in ischemic tissues. In addition, VEGF plays an important role in bone repair and regeneration by promoting angiogenesis. Street et al. reported that treatment of mice with a soluble, neutralising VEGF receptor reduced angiogenesis, bone formation, and callus mineralisation in femoral fractures and inhibited healing of a tibial cortical bone defect, while exogenous VEGF enhanced blood vessel formation, ossification, and new bone (callus) maturation in mouse femur fractures, and it promoted bony bridging of a rabbit radius segmental gap defect [85]. Tarkka et al. confirmed that VEGF promotes bone healing by accelerating endochondral bone formation based on adenoviral-VEGF gene transfer by injecting adenoviral VEGF-A into the muscle layer surrounding the bone defect [86]. In other studies, Geiger et al. and Huang et al. also observed the same results [87, 88].

Considering that HIF degradation is regulated by PHDs, small molecule inhibitors of PHD can be used to selectively activate the HIF pathway to facilitate bone regeneration. Shen et al. directly injected DFO and DMOG, two small molecule PHD inhibitors, at fracture sites to activate HIF-1 in a stabilised murine femur fracture model [40]. They found that the vascularity increased at 14 days and the callus size increased as assessed by microCT at 28 days, suggesting that HIF activation is a viable approach to increase vascularity and bone formation following skeletal trauma. Stewart et al. activated the HIF pathway using deferoxamine combined with a biodegradable, weight-bearing scaffold to promote healing in a femoral segmental defect model [41]. Their study revealed that DFO improves angiogenesis and stiffness of bone healing in segmental defects as assessed by angiography and biomechanical testing. Zhang et al. implanted deferoxamine-loaded true bone ceramic scaffolds into 15 mm rabbit radial defects [42]. After 8 weeks, the reconstruction of bone defects was evaluated with X-ray, microCT, and histological examinations. The examinations showed considerably increasing new bone in deferoxamine-loaded true bone ceramic scaffolds, and many cavities in the new bone area were occupied by bone marrow elements and blood vessels.

6.2. Osteoporosis. Osteoporosis is a disease characterised by low bone mineral density and microstructural damage to bone tissue, leading to increased bone fragility and an increased risk of bone fracture. The decrease in bone mineral density is the consequence of an unbalanced bone remodelling process, with the occurrence of more bone resorption than bone formation. Osteoporosis predominantly affects postmenopausal women, and it causes great suffering in families and modern society. Current therapeutic options for the treatment of osteoporosis include antiresorptive drugs, especially bisphosphonates and more recently denosumab, as well as calcitonin and, for women, oestrogens or selective oestrogen receptor modulators. However, all these drugs have limitations in that they lead to a low turnover state, which means that bone formation also decreases with the decrease in bone remodelling activity.

Recently, some studies have noted that HIF-1α can regulate the bone formation ability of osteoblasts in postmenopausal osteoporosis. Liu et al. found that in female mice in which the HIF-1α gene in osteoblasts was conditionally knocked out, the trabecular number, volume, thickness, bone density, and some cytokines associated with osteogenesis and angiogenesis decreased significantly compared with wild-type mice 8 weeks after the mice were ovariectomised [89]. A similar investigation performed by Zhao et al. showed that in female mice in which the HIF pathway in osteoblasts was activated via disruption of the HIF-degrading von Hippel-Lindau (VHL) protein, the bone structural and mechanical quality parameters did not change substantially after the mice were ovariectomised [48]. However, in the normal mice, the bone mineral density and mechanical strength decreased with deteriorated bone microarchitecture after the ovariectomy. This may offer a potential therapeutic target and options for the treatment of osteoporosis.

6.3. Distraction Osteogenesis. Distraction osteogenesis (DO) is a remarkable surgical method used to lengthen limbs or restore bone defects through an intramembranous process largely devoid of the formation of cartilage. Moreover, it has been used as a model for studying the cellular mechanisms involved in angiogenic-osteogenic coupling during bone repair and regeneration. During the progress of DO, intramembranous bone formation is induced by an external fixation device that applies gradual mechanical distraction.
across the osteotomy [90]. This procedure shows a close temporal and spatial relationship between bone regeneration and angiogenesis [4]. Thus, DO is an available method to study the role of the HIF pathway in bone repair and regeneration.

It was found that during normal DO, VEGFR1 and VEGFR2 mRNAs increase in parallel with VEGF mRNA. Interestingly, the administration of an antibody blockade of VEGFR1 and VEGFR2 resulted in decreases of both bone formation and vessel volume and number [91]. He et al. studied the expression of HIF-la in a rabbit model of mandibular distraction osteogenesis by immunohistochemical and in situ hybridisation [92]. He and colleagues found that the expression of HIF-la increases in the early phase but declines with the maturation of newly formed bone, suggesting that the production of HIF-la in the distracted gap may contribute to new bone formation during gradual distraction of the mandible.

Pacicca et al. also investigated the expression of angiogenic factors during distraction osteogenesis [93]. The study showed that the expression of VEGF, assessed by immunohistochemical analysis, was localised at the leading edge of the distraction gap, where nascent osteogenesis occurs. They also detected mRNA expression of a wide variety of angiogenic factors by microarray analysis, including angiopoietins 1 and 2, both Tie receptors, VEGF-A and VEGF-D, VEGFR2, and neuropilin-1. They found that the expression of these factors is maximal during the phase of active distraction.

Wan et al. demonstrated that the HIF-la pathway is activated during bone repair and can be manipulated genetically and pharmacologically to promote bone healing [43]. Genetically, they developed a mutant mouse model lacking pVHL in osteoblasts to activate the HIF signalling pathway. They found that genetic activation of the HIF-la pathway promotes angiogenesis and enhances bone regeneration in distraction osteogenesis. The distraction gap is rapidly filled with blood vessels, and this is followed by increases in bone volume and callus strength. By contrast, in mice lacking HIF-la, fewer blood vessels and less bone were observed. Pharmacologically, they used deferoxamine (DFO) and l-mimosine (l-mim), known PHD inhibitors, to activate the HIF signalling pathway, and they obtained similar results. In a similar study, Donneys et al. stated that DFO significantly increased bone structural and mechanical quality parameters such as bone volume fraction (BVF), bone mineral density (BMD), and ultimate load (UL) compared to nontreated controls during mandibular distraction osteogenesis [44].

Although PHD inhibitors have been applied in bone repair and regeneration, the PHD inhibitors used are mostly nonspecific. The application of novel PHD inhibitors such as TM6008, TM6089, and GSK360A in bone healing has not been reported. Future studies may focus on applying novel PHD inhibitors in bone regeneration and exploring novel therapeutic approaches and agents to facilitate bone repair.

6.4. Bone Tumours. Hypoxia is the most common phenomenon in solid tumours because of the increasing expenditure of oxygen by uncontrolled growth of the tumour cells. As important transcription factors that transactivate a series of hypoxia-associated genes to adapt to hypoxia, HIFs are also closely related to tumours. In the past two decades, the discovery of hypoxia-inducible factor-1 (HIF-1) led to a better understanding of the mechanism of tumour hypoxia. HIF-1 immortalises tumours by activating the transcription of its target genes, which regulate several biological processes including angiogenesis, cell proliferation, survival, glucose metabolism, and migration. Angiogenesis represents an essential step in tumour proliferation, expansion, and metastasis [94]. HIFs can promote the expression of a number of angiogenic factors, including VEGF, angiopoietins (ANG-1 and -2), platelet-derived growth factor-B (PDGF-B), and the TIE-2 receptor [95]. It was reported that HIF-la null mutations severely retard tumour growth by reducing the expression of VEGF [96] and that overexpression of HIF-la is associated with resistance to cancer chemotherapy and increased patient mortality. Thus, HIF-1 inhibitors appear to have antitumor effects; they offer a novel therapeutic strategy and are receiving increasing attention. Considering the potential antitumor effects of HIF-1 inhibitors, a number of chemical inhibitors and protein and nucleic acid inhibitors have been identified.

It was reported that the suppression of HIF-la activity by trichostatin A downregulates hypoxia-response genes and hypoxia-induced angiogenesis in human osteosarcoma [97]. By using the small hairpin RNA (shRNA) technique, Wu et al. found that silencing HIF-la decreased the expression of VEGF in the human osteosarcoma cell line SaOS-2 under hypoxia [98]. In another study by Wu Q et al., they investigated the inhibitory effects of small hairpin RNA targeting the HIF-la gene on the growth of osteosarcoma in vitro and in vivo. It was found that cellular growth and survival activities decreased in SaOS-2 cells transfected with shRNA targeting HIF-la under hypoxia, and the rates of formation and growth of xenograft tumours in mice transfected with shRNA targeting HIF-la slowed significantly [99].

At present, a large number of HIF-1 inhibitors have been developed and applied in anticancer research. However, research on the antitumor effects of HIF-1 inhibitors in bone tumours is not sufficient. Future studies should focus on the effects of HIF-1 inhibitors on angiogenesis in bone tumours and their therapeutic efficacy.

7. Conclusion

The HIF pathway participates in many mammalian physiological processes. HIFs are involved in angiogenesis, erythropoiesis, energy metabolism, and cell fate decisions. Genetic and pharmacological manipulations of HIFs have been proven to activate the HIF pathway in vitro and in vivo and to stimulate HIF-mediated pathways even under normoxic conditions (Table 1). This approach activates the beneficial aspects of the HIF system, and the HIF pathway has been a therapeutic target for the treatment of hypoxic-ischemic diseases. Moreover, the HIF pathway plays an important role in the adaptation of tumour cells to hypoxia by activating target genes that regulate angiogenesis, cell proliferation, survival,
glucose metabolism, and migration. The inhibitors of HIF-1 offer a novel method for the treatment of bone tumours.

Increasing evidence suggests that the HIF pathway plays a critical role in angiogenic-osteogenic coupling during bone repair and regeneration. Indeed, the HIF pathway has been used as an approach to accelerate bone healing following injury. Considering the experimental observations reviewed in this paper, we present an angiogenic-osteogenic coupling model that describes the procedure from the sensing of reduced oxygen and nutrient availability by resident bone cells, the initiation of angiogenesis, to ultimate bone repair (Figure 2). First, resident cells such as chondrocytes, osteocytes, and osteoblasts sense reduced oxygen tension via the HIF pathway. Then, the HIF pathway is activated, and both HIFs and their target genes including VEGF are upregulated. Finally, the HIFs and VEGF promote bone regeneration via at least one of two mechanisms. One of the two mechanisms is that VEGF functions to stimulate new blood vessel formation and invasion into bone. The newly formed blood vessels deliver chemical signals that induce bone formation and carry more osteoblast progenitors that subsequently mature and form new bone. Additionally, the endothelial cells of the newly formed blood vessels can induce osteoblast differentiation of bone marrow mesenchymal stem cells. The other mechanism is that the HIF pathway may function in an autocrine or paracrine mode to directly stimulate mesenchymal stem cell and osteoblast differentiation, proliferation, and migration independent of angiogenesis, thereby accelerating bone mineralisation. This may indirectly induce the formation of blood vessels by promoting the migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in view of the effects of mesenchymal stem cells on endothelial cells.

Much work needs to be done in the future to further elucidate the cellular and molecular mechanisms of angiogenic-osteogenic coupling. This work may lead to a better understanding of the precise communication between angiogenesis and osteogenesis and provide novel methods to accelerate bone repair and regeneration or inhibit the growth of bone tumours.

**Abbreviations**

- **HIFs**: Hypoxia-inducible factors
- **PHDs**: Prolyl hydroxylase domain proteins
- **VEGF**: Vascular endothelial growth factor
- **MSCs**: Mesenchymal stem cells
- **FKBP38**: FK506-binding protein 38
- **bHLH-PAS**: The basic Helix-Loop-Helix PER-ARNT-SIM
- **EPO**: Erythropoietin
- **HO-1**: Hemeoxygenase-1
- **iNOS**: Inducible nitric oxide synthase
- **Glut-1**: The glucose transporter protein 1
- **IGF-2**: Insulin-like growth factor 2
- **ODD**: Oxygen dependent degradation domain
- **VHL**: Von Hippel-Lindau tumor suppressor protein
This study was supported by the National Natural Science Foundation of China (Grant nos. 81101363 and 81371944).

References

[1] M. Ema, K. Hirota, J. Mimura et al., “Molecular mechanisms of transcription activation by HLF and HIFα in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300,” The EMBO Journal, vol. 18, no. 7, pp. 1905–1914, 1999.

[2] M. Nangaku, Y. Izuhara, S. Takizawa et al., “A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2548–2554, 2007.

[3] S. Barth, J. Nesper, P. A. Hasgall et al., “The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability,” Molecular and Cellular Biology, vol. 27, no. 10, pp. 3758–3768, 2007.

[4] A. Danis, “Mechanism of bone lengthening by the Ilizarov technique,” Bulletin et Memoires de l’Academie Royale de Medecine de Belgique, vol. 156, no. 1-2, pp. 107–112, 2001.

[5] G. L. Wang, B.-H. Jiang, and G. L. Semenza, “Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1,” Biochemical and Biophysical Research Communications, vol. 216, no. 2, pp. 669–675, 1995.

[6] H. Li, H. P. Ko, and J. P. Whitlock Jr., “Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIFα,” Journal of Biological Chemistry, vol. 271, no. 35, pp. 21262–21267, 1996.

[7] G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003.

[8] W.-C. Hon, M. I. Wilson, K. Harlos et al., “Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL,” Nature, vol. 417, no. 6892, pp. 975–978, 2002.

[9] J.-H. Min, H. Yang, M. Ivan, F. Geyer, W. G. Kaelin Jr., and N. P. Pavietich, “Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling,” Science, vol. 296, no. 5574, pp. 1886–1889, 2002.

[10] M. Ivan, K. Kondo, H. Yang et al., “HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing,” Science, vol. 292, no. 5516, pp. 464–468, 2001.

[11] N. Masson, C. Willam, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe, “Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation,” The EMBO Journal, vol. 20, no. 18, pp. 5197–5206, 2001.

[12] P. H. Maxwell, M. S. Wiesener, G.-W. Chang et al., “The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis,” Nature, vol. 399, no. 6733, pp. 271–275, 1999.

[13] M. Ohh, C. W. Park, M. Ivan et al., “Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel—lindau protein,” Nature Cell Biology, vol. 2, no. 7, pp. 423–427, 2000.

[14] M. Hirsilä, P. Koivunen, V. Günzler, K. I. Kivirikko, and J. Myllyharju, “Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor,” Journal of Biological Chemistry, vol. 278, no. 33, pp. 30772–30780, 2003.

[15] N. Sang, J. Fang, V. Srinivas, I. Leshchinsky, and J. Caro, “Carboxyl-terminal transactivation activity of hypoxia-inducible factor α is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP,” Molecular and Cellular Biology, vol. 22, no. 9, pp. 2984–2992, 2002.

[16] Z. Arany, L. E. Huang, R. Eckner et al., “An essential role for p300/CBP in the cellular response to hypoxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 12969–12973, 1996.

[17] R. H. Wenger, D. P. Stiehl, and G. Camenisch, “Integration of oxygen signaling at the consensus HRE,” Science’s STKE, vol. 2005, no. 306, article re12, 2005.

[18] P. Koivunen, P. Taina, J. Hyvärinen et al., “An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor α,” Journal of Biological Chemistry, vol. 282, no. 42, pp. 30544–30552, 2007.

[19] A. C. R. Epstein, J. M. Gleadle, L. A. McNeill et al., “C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by proline hydroxylation,” Cell, vol. 107, no. 1, pp. 43–54, 2001.

[20] R. J. Appelhöfl, Y.-M. Tian, R. R. Rava et al., “Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor,” Journal of Biological Chemistry, vol. 279, no. 37, pp. 38458–38465, 2004.

[21] E. Metzen, D. P. Stiehl, K. Doele, J. H. Marxsen, T. Hellwig-Bürgel, and W. Jelkmann, “Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element,” Biochemical Journal, vol. 387, no. 3, pp. 711–717, 2005.
[23] N. Pescador, Y. Cuevas, S. Naranjo et al., “Identification of a functional hypoxia-responsive element that regulates the expression of the egf nine homologue 3 (egfl3/phd3) gene,” Biochemical Journal, vol. 390, no. 1, pp. 189–197, 2005.

[24] J. H. Marxsen, P. Stengel, K. Doege et al., “Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-α-prolyl-4-hydroxylases,” Biochemical Journal, vol. 381, no. 3, pp. 761–767, 2004.

[25] G. D’Angelo, E. Duplan, N. Boyer, P. Vigne, and C. Frelin, “Hypoxia up-regulates prolyl hydroxylase activity. A feedback mechanism that limits HIF-1 responses during reoxygenation,” Journal of Biological Chemistry, vol. 278, no. 40, pp. 38183–38187, 2003.

[26] D. P. Stehl, R. Wirthner, J. Kóditz, P. Spielmann, G. Camenisch, and R. H. Wenger, “Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels: evidence for an autoregulatory oxygen-sensing system,” Journal of Biological Chemistry, vol. 281, no. 33, pp. 23482–23491, 2006.

[27] C. J. Schofield and P. J. Ratcliffe, “Oxygen sensing by HIF hydroxylases,” Nature Reviews Molecular Cell Biology, vol. 5, no. 5, pp. 343–354, 2004.

[28] C. Yan, K. J. Ehrlich, S. L. Wang, and D. N. Peck, “Hypoxia-inducible factor-1 is central to cardioprotection and myocardial ischemia-reperfusion injury,” Journal of the American Society of Nephrology, vol. 19, no. 1, pp. 39–46, 2008.

[29] T. Eckle, D. Kohler, R. Lehmann, K. C. E. Kasmir, and H. K. Eltzschig, “Hypoxia-inducible factor-1 is central to cardioprotection a new paradigm for ischemic preconditioning,” Circulation, vol. 118, no. 2, pp. 166–175, 2008.

[30] E. P. Cummins, F. Seeballuck, S. J. Keely et al., “The hydroxylase inhibitor dimethylxaloylglycine is protective in a murine model of colitis,” Gastroenterology, vol. 134, no. 1, pp. 156–165, 2008.

[31] M. Safran, W. Y. Kim, F. O’Connell et al., “Hypoxia-inducible factor hydroxylases protects against renal ischemia-reperfusion injury,” Journal of the American Society of Nephrology, vol. 19, no. 1, pp. 105–110, 2006.

[32] L. Yan, Y. J. Colandrea, and J. J. Hale, “Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia,” Expert Opinion on Therapeutic Patents, vol. 20, no. 9, pp. 1219–1245, 2010.

[33] C. Schneider, G. Krischke, S. Keller et al., “Short-term effects of pharmacologic HIF stabilization on vasoactive and cytotoxic factors in developing mouse brain,” Brain Research, vol. 1280, pp. 43–51, 2009.

[34] C. Rosenberger, S. Rosen, A. Shina et al., “Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney,” Nephrology Dialysis Transplantation, vol. 23, no. 11, pp. 3472–3478, 2008.

[35] W. Bao, P. Qin, S. Needle et al., “Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylation improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat,” Journal of Cardiovascular Pharmacology, vol. 56, no. 2, pp. 147–155, 2010.

[36] U. Hopfer, H. Hopfer, K. Jablonski, R. A. K. Stahl, and G. Wolf, “The novel WD-repeat protein Morgl acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3),” Journal of Biological Chemistry, vol. 281, no. 13, pp. 8645–8655, 2006.

[37] L. Claesson-Welsh and M. Welsh, “VEGFA and tumour angiogenesis,” Journal of Internal Medicine, vol. 273, no. 2, pp. 114–127, 2013.

[38] Y.-X. Li, S.-J. Ding, L. Xiao, W. Guo, and Q. Zhan, “Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor α and erythropoietin,” Neuroscience Bulletin, vol. 24, no. 2, pp. 89–95, 2008.

[39] T. Hishikawa, S. Ono, T. Ogawa, K. Tokunaga, K. Sugiu, and I. Date, “Effects of desferoxamine-activated hypoxia-inducible factor-1 on the braintem II after subarachnoid hemorrhage in rats,” Neurosurgery, vol. 62, no. 1, pp. 232–240, 2008.

[40] X. Shen, C. Wan, G. Ramaswamy et al., “Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice,” Journal of Orthopaedic Research, vol. 27, no. 10, pp. 1298–1305, 2009.

[41] R. Stewart, J. Goldstein, A. Eberhardt, G. T.-M. Gabriel Chu, and S. Gilbert, “Increasing vascularity to improve healing of a segmental defect of the rat femur,” Journal of Orthopaedic Trauma, vol. 25, no. 8, pp. 472–476, 2011.

[42] W. Zhang, G. Li, R. Deng, L. Deng, and S. Qiu, “New bone formation in a true bone ceramic scaffold loaded with desferoxamine in the treatment of segmental bone defect: a preliminary study,” Journal of Orthopaedic Science, vol. 17, no. 3, pp. 289–298, 2012.

[43] C. Wan, S. R. Gilbert, Y. Wang et al., “Activation of the hypoxia-inducible factor-1 alpha pathway accelerates bone regeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 2, pp. 686–691, 2008.

[44] A. Donneys, S. D. Sheshpan, C. N. Tchanque-Fosso et al., “Deferoxamine expedites consolidation during mandibular distraction osteogenesis,” Bone, vol. 55, no. 2, pp. 384–390, 2013.

[45] L. Xi, M. Taher, C. Yin, F. Salloum, and R. C. Kukreja, “Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-α and AP-1 and INOS signaling,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 287, no. 6, pp. H2369–H2375, 2004.

[46] M. Philipp, L. Cui, B. Ludolph et al., “Deferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 290, no. 1, pp. H450–H457, 2006.

[47] M. M. Hsieh, N. S. Linde, A. Wynter et al., “HIF-1α prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques,” Blood, vol. 110, no. 6, pp. 2140–2147, 2007.

[48] Q. Zhao, X. Shen, W. Zhang, G. Zhu, J. Qi, and L. Deng, “Mice with increased angiogenesis and osteogenesis due to conditional activation of HIF pathway in osteoblasts are protected from ovariectomy induced bone loss,” Bone, vol. 50, no. 3, pp. 763–770, 2012.

[49] Y. Wang, C. Wan, S. R. Gilbert, and T. L. Clemens, “Oxygen sensing and osteogenesis,” Annals of the New York Academy of Sciences, vol. 1117, pp. 1–11, 2007.

[50] E. R. Rios, R. J. Skoracki, and A. B. Mathur, “GNAS1 and PHD2 short-interfering RNA support bone regeneration in an ovine model,” Clinical Orthopaedics and Related Research, vol. 470, no. 9, pp. 2541–2553, 2012.
reperfusion injury,” *Circulation Research*, vol. 98, no. 1, pp. 133–140, 2006.

[52] G. Czibik, J. Gravning, V. Martinov et al., “Gene therapy with hypoxia-inducible factor I alpha in skeletal muscle is cardioprotective in vivo,” *Life Sciences*, vol. 88, no. 11-12, pp. 543–550, 2011.

[53] T. Date, S. Mochizuki, A. J. Belanger et al., “Expression of constitutively stable hybrid hypoxia-inducible factor-lxα protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury,” *American Journal of Physiology—Cell Physiology*, vol. 288, no. 2, pp. C314–C320, 2005.

[54] P. Tothill and J. N. MacPherson, “The distribution of blood flow to the whole skeleton in dogs, rabbits and rats measured with microspheres,” *Clinical and Physiological Measurement*, vol. 7, no. 2, pp. 117–123, 1986.

[55] P. M. Gross, D. D. Heistad, and M. L. Marcus, “Neurohumoral regulation of blood flow to bones and marrow,” *The American Journal of Physiology*, vol. 237, no. 4, pp. H440–H448, 1979.

[56] R. C. Riddle, R. Khatri, E. Schipani, and T. L. Clemens, “Role of hypoxia-inducible factor-lα in angiogenic-osteogenic coupling,” *Journal of Molecular Medicine*, vol. 87, no. 6, pp. 583–590, 2009.

[57] G. L. Semenza, “Regulation of cancer cell metabolism by hypoxia-inducible factor I,” *Seminars in Cancer Biology*, vol. 19, no. 1, pp. 12–16, 2009.

[58] E. Schipani, H. E. Ryan, S. Didrickson, T. Kobayashi, M. Knight, and R. S. Johnson, “Hypoxia in cartilage: HIF-lα is essential for chondrocyte growth arrest and survival,” *Genes and Development*, vol. 15, no. 21, pp. 2865–2876, 2001.

[59] Y. Wang, C. Wen, L. Deng et al., “The hypoxia-inducible factor α pathway couples angiogenesis to osteogenesis during skeletal development,” *Journal of Clinical Investigation*, vol. 117, no. 6, pp. 1616–1626, 2007.

[60] C. C. Tsai, T. L. Yew, D. C. Yang, W. H. Huang, and S. C. Hung, “Benefits of hypoxia culture on bone marrow multipotent stromal cells,” *American Journal of Blood Research*, vol. 2, no. 3, pp. 148–159, 2012.

[61] C.-C. Tsai, Y.-J. Chen, T.-L. Yew et al., “Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST,” *Blood*, vol. 117, no. 2, pp. 459–469, 2011.

[62] S.-C. Hung, R. R. Pochampally, S.-C. Hsu et al., “Short-term exposure of multipotent stromal cells to low oxygen decreases their expression of CX3CR1 and CXCR4 and their engraftment in vivo,” *PLoS ONE*, vol. 2, no. 5, article e416, 2007.

[63] H. Okuyama, B. Krishnamachary, Y. F. Zhou, H. Nagasawa, M. Bosch-Marce, and G. L. Semenza, “Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor α,” *Journal of Biological Chemistry*, vol. 281, no. 22, pp. 15554–15563, 2006.

[64] C. Fehrer, R. Brunauer, G. Laschober et al., “Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan,” *Aging Cell*, vol. 6, no. 6, pp. 745–757, 2007.

[65] C. Holzwarth, M. Vaegler, F. Gieseke et al., “Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells,” *BMC Cell Biology*, vol. 11, article 11, 2010.

[66] D.-C. Yang, M.-H. Yang, C.-C. Tsai, T.-F. Huang, Y.-H. Chen, and S.-C. Hung, “Hypoxia inhibits osteogenesis in human mesenchymal stem cells through direct regulation of RUNX2 by TWIST,” *PLoS ONE*, vol. 6, no. 9, Article ID e23965, 2011.

[67] S. Lord-Dufour, I. B. Copland, L.-C. Levros Jr. et al., “Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-lα: targeting G6PT with mubamabatin analogs in hypoxic mesenchymal stromal cells,” *Stem Cells*, vol. 27, no. 3, pp. 489–497, 2009.

[68] C. Penna, M.G. Perrelli, J. P. Karam et al., “Pharmacologically active microcarriers influence VEGF-A effects on mesenchymal stem cell survival,” *Journal of Cellular and Molecular Medicine*, vol. 17, no. 1, pp. 192–204, 2013.

[69] B. Chen, Y.-B. Song, Y.-H. Li, and G.-X. Pei, “Effect of vascular endothelial growth factor gene transfer on proliferation and metabolism of human bone marrow stromal cells in vitro,” *Nan Fang Yi Ke Da Xue Xue Bao*, vol. 28, no. 7, pp. 1172–1175, 2008.

[70] J. Dieter, F. Leucht, J. Waltenberger, C. Dehio, and R. E. Brenner, “VEGF-A and PIGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells,” *Biochemical and Biophysical Research Communications*, vol. 334, no. 2, pp. 561–568, 2005.

[71] H. Lin, A. Shabbir, M. Molnar et al., “Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells,” *Journal of Cellular Physiology*, vol. 216, no. 2, pp. 458–468, 2008.

[72] Z. Huang, P.-G. Ren, T. Ma, R. L. Smith, and S. B. Goodman, “Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability,” *Cytokine*, vol. 51, no. 3, pp. 305–310, 2010.

[73] Y. Liu, A. D. Berendes, S. Jia et al., “Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation,” *The Journal of Clinical Investigation*, vol. 122, no. 9, pp. 3101–3113, 2012.

[74] V. Midy and J. Plouet, “Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts,” *Biochemical and Biophysical Research Communications*, vol. 199, no. 1, pp. 380–386, 1994.

[75] U. Mayr-wollfart, J. Waltenberger, H. Hausser et al., “Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts,” *Bone*, vol. 30, no. 3, pp. 472–477, 2002.

[76] R. Gruber, B. Kandler, P. Holzmann et al., “Bone marrow stromal cells provide a local environment that favors migration and formation of tubular structures of endothelial cells,” *Tissue Engineering*, vol. II, no. 5-6, pp. 896–903, 2005.

[77] I. A. Potapova, G. R. Gaudette, P. R. Brink et al., “Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro,” *Stem Cells*, vol. 25, no. 7, pp. 1761–1768, 2007.

[78] N. B. Thebaut et al., “Whatever their differentiation status, human progenitor derived—or mature—endothelial cells induce osteoblastic differentiation of bone marrow stromal cells,” *Journal of Tissue Engineering and Regenerative Medicine*, vol. 6, no. 10, pp. e51–e60, 2012.

[79] L. C. Gerstenfeld, D. M. Cullinane, G. L. Barnes, D. T. Graves, and T. A. Einhorn, “Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation,” *Journal of Cellular Biochemistry*, vol. 88, no. 5, pp. 873–884, 2003.

[80] Z. Al-Aql, A. S. Alagl, D. T. Graves, L. C. Gerstenfeld, and T. A. Einhorn, “Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis,” *Journal of Dental Research*, vol. 87, no. 2, pp. 107–118, 2008.
[81] I. H. Choi, J. H. Ahn, C. Y. Chung, and T.-J. Cho, "Vascular proliferation and blood supply during distraction osteogenesis: a scanning electron microscopic observation," Journal of Orthopaedic Research, vol. 18, no. 5, pp. 698–705, 2000.

[82] D. E. Komatsu and M. Hadjiargyrou, "Activation of the transcription factor HIF-1 and its target genes, VEGF, HO-1, iNOS, during fracture repair," Bone, vol. 34, no. 4, pp. 680–688, 2004.

[83] C. Ferguson, E. Alpern, T. Miclau, and J. A. Helms, "Does adult fracture repair recapitulate embryonic skeletal formation?" Mechanisms of Development, vol. 87, no. 1-2, pp. 57–66, 1999.

[84] A. X. Le, T. Miclau, D. Hu, and J. A. Helms, "Molecular aspects of healing in stabilized and non-stabilized fractures," Journal of Orthopaedic Research, vol. 19, no. 1, pp. 78–84, 2001.

[85] J. Street, M. Bao, L. DeGuzman et al., "Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 15, pp. 9656–9661, 2002.

[86] Y.-C. Huang, D. Kai, K. G. Rice, P. H. Krebsbach, and D. J. Mooney, "Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration," Journal of Bone and Mineral Research, vol. 20, no. 5, pp. 848–857, 2005.

[87] X.-D. Liu, L.-F. Deng, J. Wang et al., "The regulation of hypoxia inducible factor-1alpha on osteoblast function in postmenopausal osteoporosis," Zhonghua Wai Ke Za Zhi, vol. 45, no. 18, pp. 1274–1278, 2007.

[88] G. A. Ilizarov, "Clinical application of the tension-stress effect for limb lengthening," Clinical Orthopaedics and Related Research, no. 250, pp. 8–26, 1990.

[89] K. A. Jacobsen, Z. S. Al-Aql, C. Wan et al., "Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling," Journal of Bone and Mineral Research, vol. 23, no. 5, pp. 596–609, 2008.

[90] J. F. He, Z. J. Xie, H. Zhao et al., "Immunohistochemical and in-situ hybridization study of hypoxia inducible factor-1α and angiopoietin-1 in a rabbit model of mandibular distraction osteogenesis," International Journal of Oral and Maxillofacial Surgery, vol. 37, no. 6, pp. 554–560, 2008.

[91] M. M. Hickey and M. C. Simon, "Regulation of angiogenesis by hypoxia and hypoxia-inducible factors," Current Topics in Developmental Biology, vol. 76, pp. 217–257, 2006.

[92] H. E. Ryan, J. Lo, and R. S. Johnson, "HIF-1α is required for solid tumor formation and embryonic vascularization," The EMBO Journal, vol. 17, no. 11, pp. 3005–3015, 1998.